Stocks
Funds
Screener
Sectors
Watchlists
IMGN

IMGN - ImmunoGen Inc Stock Price, Fair Value and News

$31.23 
Market Closed

IMGN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IMGN Price Action

IMGN RSI Chart

IMGN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

IMGN Valuation

IMGN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

IMGN Fundamentals

IMGN Revenue

IMGN Earnings

IMGN Profitability

IMGN Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023120.6M189.6M287.6M0
202292.2M89.4M95.6M108.8M
2021134.7M136.6M127.7M69.9M
202087.0M86.5M91.4M132.3M
201942.2M48.5M50.8M82.3M
2018106.8M77.0M79.5M53.4M
201757.4M89.0M89.8M115.4M
201665.2M60.0M52.8M48.6M
201578.7M85.5M87.2M56.9M
201458.0M59.9M55.9M74.1M
201334.7M35.5M48.7M76.1M
201219.9M16.4M17.9M12.9M
201118.0M19.3M18.4M21.9M
2010013.9M15.3M16.6M
IMGN
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
 CEO
 WEBSITEimmunogen.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES277